Otsuka Pharmaceutical to Acquire Jnana Therapeutics, Expanding its Autoimmune Portfolio and Drug Discovery Technologies
Shots:
- Otsuka has agreed to acquire Jnana, expanding its autoimmune portfolio & drug discovery tech for $800M upfront at closing & $325M development & regulatory milestones. Acquisition will be concluded in Q3’24
- The acquisition adds Jnana’s RAPID (next-gen. chemoproteomics platform for drug discovery) & JNT-517 (small molecule SLC6A19 inhibitor) to Otsuka’s portfolio. Jnana is also discovering a small molecule in the autoimmune disease area to target IRF3
- JNT-517 is being assessed under P-I, with parts A & B finding PK of SAD & MAD, part C determining the relative bioavailability of tablet & suspension formulations in healthy subjects and part D finding the effects on urinary Phe & other amino acids in PKU patients. Its registrational study is anticipated in 2025
Ref: Jnana Therapeutics | Image: Jnana Therapeutics
Related Post: Jnana Therapeutics Entered into a Second Collaboration and License Agreement with Roche to Discover Small Molecule Drugs
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
